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Abstract
Background: In many malaria-endemic countries, increasing resistance may soon compromise the efficacy of
sulphadoxine-pyrimethamine (SP) for intermittent preventative treatment (IPT) of malaria in pregnancy. Artemisinin-
based IPT regimens represent a promising potential alternative to SP. Pharmacokinetic and safety data supporting
the use of artemisinin derivatives in pregnancy are urgently needed.
Methods: Subjects included pregnant women with asymptomatic falciparum parasitaemia between 22-26 weeks
(n = 13) or 32-36 weeks gestation (n = 13), the same women at three months postpartum, and 25 non-pregnant
parasitaemic controls. All subjects received 200 mg orally administered AS. Plasma total and free levels of AS and
its active metabolite DHA were determined using a validated LC-MS method. Non-compartmental pharmacokinetic
analysis was performed using standard methods.
Results: All pregnant women delivered live babies. The median birth weight was 3025 grams [range 2130, 3620]; 2
of 26 babies had birth weights less than 2500 grams. Rates of parasite clearance by 12 hours post-dose were high
and comparable among the groups. Rapid elimination of AS was observed in all three groups. The 90% CI for the
pregnancy:postpartum ratio of geometric means for total and free AUC fell within the pre-specified 0.66 - 1.50
therapeutic equivalence interval. However, more pronounced pharmacokinetic differences were observed between
the pregnancy and control subjects, with the 90% CI for the pregnancy:control ratio of geometric means for both
total 0.68 (90% CI 0.57-0.81) and free AUC 0.78 (90% CI 0.63-0.95) not fully contained within the 0.66 - 1.50 interval.
All subjects cleared parasites rapidly, and there was no difference in the percentage of women who were
parasitaemic 12 hours after dosing.
Conclusions: A single dose of orally administered AS was found to be both effective and without adverse effects
in this study of second and third trimester pregnant women in the DRC. Although DHA AUC during pregnancy
and postpartum were similar, the AUC for the pregnant group was less than the non-pregnant controls. The
findings of this study suggest that additional studies on the pharmacokinetics of AS in pregnant women are
needed.
Trial Registration: ClinicalTrials.gov: NCT00538382
* Correspondence: meshnick@unc.edu
2UNC Gillings School of Global Public Health Department of Epidemiology,
3301 MHRCChapel Hill NC 27599-7435, USA
Full list of author information is available at the end of the article
Onyamboko et al. Malaria Journal 2011, 10:49
http://www.malariajournal.com/content/10/1/49
© 2011 Onyamboko et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Background
Pregnant women are particularly susceptible to malaria,
which can lead to intrauterine growth restriction, low
birth weight, prematurity, and other poor birth out-
comes [1-7]. In order to protect pregnant women
against malaria, WHO recommends intermittent preven-
tive treatment (IPT) with sulphadoxine-pyrimethamine
(SP) in stable transmission areas. Unfortunately, rates of
SP resistance are now quite high in most of the world.
For example, Plasmodium falciparum resistance to SP is
greater than 57% in the eastern part of the Democratic
Republic of Congo (DRC) [8-10]. The growing threat of
SP resistance has resulted in substantial concern that SP
may become ineffective for IPT in the very near future.
Therefore, there is an urgent need to identify efficacious
alternative drug regimens [11,12].
Artemisinin-based combination therapy (ACT) is the
current first-line treatment for acute malaria in most
malaria-endemic countries [1]. Currently, recommended
ACT dosage regimens are based on studies conducted in
non-pregnant patients; however, the pharmacokinetics of
many drugs is altered during pregnancy. WHO endorses
the use of ACT for patients in the second and third trime-
sters of pregnancy with acute uncomplicated falciparum
malaria [13], but specific dosing recommendations for
pregnant women have not been developed due to insuffi-
cient pharmacokinetic data in this population. There are
also safety concerns regarding the use of artemisinin deri-
vatives in pregnancy, particularly in the first trimester. In
response to evidence from animal studies of artemisinin-
associated embryotoxicity [14], WHO guidelines constrain
the use of these derivatives in the first trimester to cases of
therapeutic failure with alterative agents [13].
Additional pharmacokinetic and safety information
regarding the use of artemisinin derivatives in pregnancy
are needed [15-18]. To date, no pharmacokinetic study
for an artemisinin derivative has been conducted that
included postpartum or non-pregnant controls. Addi-
tionally, no such pharmacokinetic study has been con-
ducted with asymptomatic parasitaemic women, the
candidate population for IPT. This paper reports the
results of a safety and pharmacokinetic study of a single
oral dose of artesunate (AS) given to asymptomatic but
parasitaemic pregnant women with P. falciparum infec-
tion, the same women three months postpartum, and a
parallel parasitaemic non-pregnant control group.
Methods
Study population
The study was conducted at Maternité des Soeurs de
Saint Marc de Kingasani, the largest maternity service in
Kinshasa. All women from 18 to 40 years of age pre-
senting for antenatal care at less than 22 weeks of gesta-
tion assessed on last menstrual period (LMP), were
screened for eligibility. Gestational age (GA) was con-
firmed by ultrasound using the Hadlock method [19].
Women with gestational ages between 8 and 21 weeks
(inclusive) were invited to participate in the study.
Women were asked during to return during the second
trimester of pregnancy (22-26 weeks GA); those not
enrolled during the second trimester were screened
again during the third trimester (32-36 weeks). Eligibility
for the study was established during the women’sr e t u r n
visits. Eligibility criteria included the following: no fever
(temperature < 37.5°C), infection with P. falciparum
(parasite count between 200 to < 300,000 parasites/μL),
haematocrit ≥30%, HIV seronegativity, and the absence
of other major medical problems (e.g. diabetes, chronic
hypertension, etc.).
To determine if women met the eligibility criteria, a
complete medical history and physical examination was
performed by a study physician; sociodemographic data
was collected by a study nurse. Haematocrit was mea-
sured using a microhaematocrit centrifuge (Hawksley
Haematospin 1400, Hawksley & Sons, Ltd, UK). Thick
and thin blood films were stained with Giemsa and then
read to determine parasite species and the density of
P. falciparum asexual stages. Parasite density, based on
examination of at least 200 high-power microscope fields,
was calculated as (# trophozoites/#white blood cells)
*6000. Human Immunodeficiency Virus (HIV) serology
was determined using the Determine 1/2 HIV Test Kit
(Inverness Medical Professional Diagnostics, Princeton,
NJ). Liver function was assessed by measuring aspartate
aminotransferase (AST) and alanine aminotransferase
(ALT) in plasmaPiccolo Portable Chemistry Analyser,
Abaxis, USA). Alpha-1-Acid glycoprotein was deter-
mined in serum samples using radial immunodiffusion
(Kent Laboratories, Bellingham, WA, USA).
There were two groups of non-pregnant controls. One
group of controls (n = 26) was comprised of the preg-
nant study subjects at their three month postpartum vis-
its. The second group of controls (n = 25) consisted of
malaria-infected, asymptomatic non-pregnant women.
Women were recruited from the area around the hospi-
tal and from one suburban health center. Interested
women were directed to the research center where they
were tested to assess eligibility using the same criteria as
the pregnant cases.
In order to confirm malaria infection, DNA was later
extracted from dried blood spots and analysed by real
time PCR using pan-species primers and probe [20].
Ethical clearance and consent
The study protocol was approved by the ethics commit-
tees of Kinshasa School of Public Health, the University
of North Carolina at Chapel Hill, and RTI International.
The study was first introduced to the pregnant women
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obtain consent for early ultrasound screening. Consent
for laboratory screening was obtained from these
women when they returned during their second or third
trimester of pregnancy, and from the non-pregnant con-
trols at the time of enrollment. Consent for the two
days inpatient was obtained from all subjects after deter-
mining eligibility.
Treatment and sampling
Study subjects received an oral dose of 200 mg AS as four
50 mg tablets (manufactured by Guilin Pharmaceutical
C o .L t d ,G u a n g x i ,R e p u b l i co fC h i n a )a f t e raf o u r - h o u r
fasting period. The four tablets were given orally with
240 mL water under medical supervision. A catheter was
inserted into a forearm vein for pharmacokinetic sample
collection and flushed after each blood draw with saline
solution. Blood (5 ml) was drawn from the IV catheter
within a 30 minute period before drug intake and then at
the following times after AS intake: 0.25, 0.5, 0.75, 1, 1.5
2, 3, 4, 6, and 8 hours. Sodium fluoride/potassium oxalate
was used as an anticoagulant. Blood for malaria smears
were taken by finger prick at pre-dose and at 12, 24, 30,
36, 42 and 48 hours post-dose. Malaria smears were also
performed on days 7, 14 and 28.
Blood samples were centrifuged immediately at -4°C
(1,100 × g/or 2600 rpm, 10 min; Eppendorf refrigerated
centrifuge) and the plasma initially stored in liquid
nitrogen before being transferred to a -80°C freezer.
Twenty-four hours after receiving AS, malaria-infected
women received 1725 mg SP to complete malaria treat-
ment in accordance with National Malaria Control Pro-
gram guidelines. The persistence of malaria infection
and adverse events were tracked for 28 days after SP
administration. Babies born from the pregnant women
cohort were followed until one year of age and develop-
ment assessed.
Drug assay
Plasma concentrations of AS and its active metabolite
dihydroartemisinin (DHA) were determined using a vali-
dated liquid chromatography-mass spectrometric method
described by Naik et al [21] with slight modifications.
Briefly, AS, DHA and the internal standard artemisinin
were extracted from 0.25 mL of human plasma using solid
phase extraction. The reconstituted extracts were chroma-
tographed isocratically and the compounds detected and
quantified by mass spectroscopy. The lower limit of quan-
tification for both AS and DHA was 1 ng/mL. Unbound
DHA was assayed using ultrafiltration.
Pharmacokinetic and statistical analysis
Plasma AS and DHA concentration data were analyzed
by noncompartmental methods using the program
WinNonlin, version 5.2 (Pharsight, Mountain View,
CA). Specifically, Cmax and Tmax were taken from
observed concentrations and the terminal slope, lz,
determined for DHA by non-linear regression of the
terminal portion of the concentration vs. time profile
using a 1/Y weighting. The DHA elimination half-life
was calculated as 0.693/lz. The area under the DHA
concentration-time curve (AUCtotal) was determined
using the trapezoidal method and total DHA concentra-
tions, with extrapolation of the AUC after the final con-
centration estimated as Clast/lz. The apparent plasma
clearance (CL/F) was determined as Dose/AUCtotal and
apparent volume of distribution (Vd/F) calculated as
Dose/(lz *A U C total) where the AS dose was assumed to
be totally and exclusively converted to DHA. Thus the
DHA dose was assumed to be equal to the AS dose on
a molar basis (DHA dose = AS dose * (284.35/384.42)),
the latter ratio representing the molecular weights of
D H Aa n dA S .T h eD H Af r e ef r a c t i o n( F F )w a sd e t e r -
mined as the ratio of unbound/total drug concentration
at each time point where both measurements were col-
lected, with mean FF calculated for each participant
within a pharmacokinetic visit. The area under the
unbound DHA concentration-time curve (AUCfree)w a s
calculated as FF*AUCtotal.T h eA U Co fA Sw a sa l s o
determined using the trapezoidal method. Concentra-
tions below the lower limit of quantification were
assigned a value of zero. The terminal slope of the AS
concentration profile could not be estimated due to the
limited samples after Cmax with concentrations above
the lower limit of quantification.
The primary pharmacokinetic outcome measured to
assess dosing adequacy was DHA AUCfree.T h eA U C s
for unbound DHA during pregnancy and postpartum
were compared using each subject as her own control.
The ratio of the AUC during pregnancy to the AUC at
postpartum (after log transformation) was considered a
measure of the impact of pregnancy on systemic expo-
sure. The interval between population ratios of 0.66 and
1.5 was defined as an interval of “no effect” of preg-
nancy on pharmacokinetics. The “no effect” interval was
selected based on the dose-ranging study by Angus and
coworkers [22]. Their sigmoid Emax pharmacodynamic
model suggested that the dose with 50% maximal effect
on parasite clearance time (PCT) was 1.46 mg/kg or
~100 mg, with a sharp increase in response around this
value (Hill slope coefficient of 10). Based on these data
and available formulation strengths, we chose an expo-
sure of 66% for non-pregnant women (equivalent to 132
mg) as the lower bound of our no-effect window. If the
90% confidence interval (CI) of pregnancy/postpartum
DHA AUCfree was determined to be within the 0.66 and
1.5 interval, then the DHA exposure was deemed as
clinically equivalent between pregnancy and postpartum.
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software, version 9.2 (SAS Institute, Inc., Cary, NC,
2008). For comparisons involving non-compartmental
parameters, p-values provided with geometric mean esti-
mates and 90% CIs were based on (paired or 2-sample)
t-tests (on logged data, except as noted) and with med-
ians were based on (signed rank or rank sum) Wilcoxon
tests. Spearman correlations were used to look for asso-
ciations among the pregnant and control population. All
p-values were 2-sided.
Results
Patients
Between May 2007 and November 2008, 13 pregnant
women were enrolled in their second trimester and 13
in their third trimester. Twenty-five non-pregnant
women with asymptomatic falciparum malaria were also
enrolled. The demographic and medical characteristics
of the three groups are shown in Table 1. There were
no significant differences among any of the three groups
in age, height, or education level. All women had nor-
mal temperatures, normal blood pressures, a haemato-
crit ≥ 30%, negative HIV tests result, normal physical
exams and no histories of chronic illness or of drug
intake (other than antipyretics). Pregnant women had a
significantly lower haematocrit and higher parity.
The median parasite densities at screening were 528
parasites/μL of blood (interquartile range: 372 - 842) in
the pregnant group and 807 parasites/μL (interquartile
range: 325 - 2215) in the non-pregnant group; these were
not significantly different (Table 2). All were P. falciparum
monoinfections, except for one pregnant case with a
mixed infection (P. falciparum and Plasmodium malar-
iae). Antenatal women in Window 1 received slightly
higher doses on a mg/kg dosage than those in Window 2,
but there were no significant differences between the preg-
nant women and their controls.
Pharmacodynamics
Parasitaemia was confirmed in all subjects by PCR at the
time of recruitment. However, two pregnant women and
11 non-pregnant controls were microscopically aparasi-
taemic by the time the pharmacokinetic experiment
started, usually a day later. Of the 24 pregnant women
who were parasitaemic at t = 0, 21 (87.5%) were aparasi-
taemic at 12 hrs (Table 2). Similarly, 13 of the 14 (93%)
non-pregnant controls with parasites at t = 0 were apar-
asitaemic at 12 hours. One pregnant woman was parasi-
taemic on day 28. Two others had gametocytes on day
7, one of whom also had gametocytes on day 14. Two
other women from the pregnant group were parasitae-
mic at three months postpartum; one of these had a
mixed infection with (P. falciparum and P. malariae).
There were no significant differences between pregnant
cases and controls in the percentage of women who
were non-parasitaemic at 12 hours (Table 2).
Pharmacokinetics
In all three groups, AS was rapidly hydrolyzed to DHA,
with AS concentrations below the lower limit of quanti-
fication (1 ng/mL) after 4 hours in all but two samples.
The median AS AUCs were 205, 132 and 187 ng*h/mL
for pregnancy, postpartum and non-pregnant women,
respectively, with AUCs ranging among the subjects by
more than 17-fold.
The median plasma concentration profiles of DHA in
the three groups are shown in Figure 1. The pharmaco-
kinetic parameter estimates for DHA are summarized in
Table 3. The pregnancy:postpartum, pregnancy:control,
and postpartum:control ratios of geometric means for
those parameters are shown in Table 4. Most DHA
pharmacokinetic parameters were similar during preg-
nancy and postpartum after accounting for the higher
free fraction during pregnancy. The estimated geometric
mean and 90% CI for the ratio of the within-subject
AUCs for free DHA for the women during pregnancy
compared with three months postpartum was 0.99 (0.85,
1.15).
The median DHA AUC was significantly higher in the
non-pregnant control group than in the pregnant group
(2787 vs 1731 ng*h/mL, respectively p = 0.0018; esti-
mated ratio of geometric means, 0.68, 90% CI [0.57,
0.81], p = 0.0004); the difference in Cmax did not reach
statistical significance (1285 vs 905 ng*h/mL respec-
tively, p = 0.24; 0.81 [0.63, 1.03], p = 0.15). The esti-
mated ratio of geometric means for free DHA AUC in
the pregnancy and control groups was 0.78, 90% CI
[0.63, 0.95], p = 0.039. The DHA free fraction was sig-
nificantly higher in the pregnancy group than control
groups but the free DHA AUC remained higher in non-
pregnant than the pregnancy group.
The relationship between free DHA AUC and body
weight is shown in Figure 2. Larger women had lower
AUCs in the malaria infected groups as weight was
inversely correlated with AUC (r
2 = 0.38, p = 0.001).
Albumin and AGP levels were lower in pregnant
women than in postpartum or non-pregnant controls
(p = 0.0003 and 0.0038, respectively, Additional file 1).
These lower binding protein concentrations are likely
responsible for the modest difference in the unbound
DHA fraction.
Safety
All pregnancies were followed until delivery and resulted
in singleton live births. There were no congenital
abnormalities. The median birth weight was 3025 grams
[range 2130, 3620] with 7.7% (2/26) weighing ≤ 2500
grams. Twenty-three of the 26 babies were followed
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Page 4 of 10Table 1 Demographic characteristics on admission of women with Plasmodium falciparum infection (pregnant cases
and non-pregnant controls)
Pregnant cases
Characteristic Window 1
(22-26 wks GA)
Window 2
(32-36 wks GA)
P-value* All Non-pregnant controls P-value†
N1 3 1 3 2 6 2 5
Age (years)‡ 21.7 ± 2.7 26.6 ± 4.4 0.0065 24.2 ± 4.4 24.8 ± 5.5 0.79
Height (m)‡ 1.6 ± 0.1 1.6 ± 0.1 0.56 1.6 ± 0.1 1.6 ± 0.1 0.77
Weight (kg)‡ 55.5 ± 8.3 63.0 ± 7.2 –– 55.2 ± 10.6 –
Postpartum (3 months) weight (kg)‡ 53.7 ± 7.6 58.0 ± 4.3 0.14 55.8 ± 6.4 0.29
BMI (kg/m
2)‡ 21.2 ± 2.8 24.4 ± 2.2 – 22.7 ± 3.0 21.0 ± 3.2 0.055
Postpartum (3 months) BMI (kg/m
2)‡ 20.3 ± 2.3 22.6 ± 1.7 0.017 21.4 ± 2.3 0.29
Education (years)‡ 9.0 ± 3.6 9.5 ± 3.0 0.57 9.2 ± 3.3 9.8 ± 3.8 0.73
Parity§ 0 (0 - 2) 1 (0 - 4) 0.081 1 (0 - 4) 0 (0 - 4) 0.0013
Parity 0.23 0.0002
0 7 (53.8) 4 (30.8) 11 (42.3) 23 (92.0)
1 5 (38.5) 3 (23.1) 8 (30.8) 0 (0.0)
2 1 (7.7) 4 (30.8) 5 (19.2) 1 (4.0)
3-4 0 (0.0) 2 (15.4) 2 (7.7) 1 (4.0)
GA at ultrasound screening (weeks)‡ 18.9 ± 1.5 18.5 ± 1.5 0.41 –– –
GA at study screening (weeks)‡ 22.4 ± 0.8 33.2 ± 1.4 –– – –
Body temperature (°C)║ 36.5
(36.1 - 36.7)
36.4
(36.2 - 36.5)
0.66 36.5
(36.1 - 36.6)
36.6
(36.4 - 36.8)
0.044
Haematocrit (%)║ 30.0
(30.0 - 30.0)
32.0
(31.0 - 33.0)
0.035 30.5
(30.0 - 33.0)
38.0
(34.0 - 38.0)
<.0001
Dosage (mg/kg) ║ 3.45
(3.17-4.17)
3.08
(2.99-3.17)
0.017 3.17
(3.08-4.00)
3.86
(3.39-4.17)
0.061
* Pregnant cases, Window 1 vs Window 2; Fisher’s exact and Wilcoxon rank sum tests.
† All pregnant cases vs. nonpregnant controls; Fisher’s exact and Wilcoxon rank sum tests.
‡ Values given as mean ± standard deviation.
§ Values given as median (range).
║ Values given as median (interquartile range).
Table 2 Pharmacodynamics of AS in malaria-infected women
Pregnant cases
Time point Window 1
(22-26 wks GA)
Window 2
(32-36 wks GA)
All Non-pregnant controls P-value*
N1 3 1 3 2 6 2 5
Screening
Parasitaemic - n (%) 13 (100.0) 13 (100.0) 26 (100.0) 25 (100.0) –
Density (where > 0)† 635
(264 - 842)
516.
(404 - 659)
528
(372 - 842)
807
(325 - 2215)
0.21
0 hours (AS dosing)
Parasitaemic - n (%) 13 (100.0) 11 (84.6) 24 (92.3) 14 (56.0) 0.0029
Density (where > 0)† 414
(179 - 857)
183
(130 - 788)
247
(151, 828)
371
(124 - 957)
0.66
12 hours
Parasitaemic - n (%) 3 (23.1) 0 (0) 3 (11.5) 1 (4.0) 0.61
Density (where > 0)† 87
(44 - 286)
–
–
87
(44 - 286)
24
–
0.44
* All pregnant cases vs. nonpregnant controls; Pearson chi-square, Fisher’s exact, and Wilcoxon rank sum tests.
† Values given as median (interquartile range).
Onyamboko et al. Malaria Journal 2011, 10:49
http://www.malariajournal.com/content/10/1/49
Page 5 of 10until one year of age and at that time had normal physi-
cal and neurological development.
There were no adverse events observed in any sub-
jects. Statistically significant increases in some labora-
tory parameters were observed (Additional file 1), but
the magnitude of these changes was small. In some
subjects, transient elevations of ALT and AST above
the upper limits of normal were observed. However,
as these elevations were less than twice the upper
limits of normal, they were considered clinically
insignificant.
Discussion
The study was conducted in the DRC, where high in
vivo resistance to SP [8-10] could soon compromise the
efficacy of SP for IPT in pregnancy. An IPT regimen
incorporating an artemisinin derivative, such as AS,
could provide a promising alternative to SP. However,
despite the broad implementation of ACTs globally for
treatment of acute falciparum malaria, questions remain
regarding the safety, pharmacokinetics, and efficacy of
artemisinin derivatives in pregnant women. The present
study was designed to assess the safety and pharmacoki-
netics of AS in a population of asymptomatic parasitae-
mic women in the second and third trimesters of
pregnancy, compared to the same women at three
months postpartum and a control group of parasitaemic
non-pregnant controls.
The pharmacokinetic analysis in this study indicates
that in all three groups of women, AS was rapidly
hydrolysed to its active metabolite DHA, becoming
undetectable within 4 hours. This observed rapid AS
disappearance is consistent with results previously
Figure 1 Median plasma concentration of DHA in pregnant,
postpartum, and non-pregnant subjects.
Table 3 DHA noncompartmental pharmacokinetic data in pregnant, postpartum, and non-pregnant women with
Plasmodium falciparum infection
Pregnant cases P-value
Parameters Ante-partum Post-partum
(3 months)
Non-pregnant
controls
Ante vs.
Post*
Ante vs. Non-pregnant
controls†
Post vs. Non-pregnant
controls†
Cmax (ng/mL) 904.6
[363.9 -
2541.9]
979.5
[414.5 -
2246.3]
1284.7
[539.8 - 3259.4]
0.89 0.24 0.090
Tmax (h) 1.50
[0.25 - 6.00]
1.50
[0.50 - 4.00]
1.52
[0.50 - 4.03]
0.95 0.57 0.34
AUCall (ng*h/
mL)
1730.5
[1034.7 -
4085.5]
2122.2
[1308.9 -
4054.9]
2787.0
[1244.8 - 6363.5]
0.0080 0.0018 0.021
AUCfree (ng*h/
mL)
398.5
[138.7 - 663.9]
373.0
[186.5 - 708.3]
504.6
[197.9 - 1301.3]
0.80 0.057 0.043
CL/F (L/h) 85.5
[36.2 - 142.9]
69.7
[36.5 - 113.0]
53.1
[23.2 - 118.8]
0.0035 0.0018 0.021
CL/F (L/kg/h) 1.39
[0.75 - 2.46]
1.26
[0.63 - 2.32]
1.07
[0.53 - 1.89]
0.033 0.0025 0.011
T½ (h) 1.28
[0.83 - 2.71]
1.63
[0.92 - 2.18]
1.41
[0.86 - 6.55]
0.021 0.28 0.27
Vd/F (L) 157.4
[59.9 - 335.9]
158.3
[66.0 - 332.7]
128.2
[38.5 - 400.1]
0.82 0.098 0.071
Vd/F (L/kg) 2.84
[1.25 - 5.33]
3.00
[1.55 - 5.37]
2.45
[0.78 - 6.56]
0.54 0.17 0.083
FF 0.21
[0.13 - 0.31]
0.19
[0.11 - 0.27]
0.18
[0.09 - 0.39]
0.014 0.031 0.82
Medians [range] and nonparametric comparison of groups.
* Wilcoxon signed rank test.
† Wilcoxon rank sum test.
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Page 6 of 10reported in the literature [23,24]. This rapid disappear-
ance precluded a comprehensive characterization of AS
pharmacokinetics. However, given that DHA is the prin-
ciple source of antimalarial activity following AS admin-
istration, the central focus of this pharmacokinetic
analysis was the assessment of DHA pharmacokinetic
alterations occurring during pregnancy. Pregnancy has
been associated with substantial changes in the absorp-
tion, distribution, metabolism and excretion of a variety
of drugs. High levels of progesterone may affect drug
absorption. Increased plasma volume and altered drug
binding protein concentrations can result in an
increased volume of distribution. Pregnancy may
increase metabolism of drugs, possibly through
increased hepatic blood flow and increased free-fraction
of drugs [25,26]. Decreased plasma concentrations of
therapeutic drugs in pregnancy can be a result of
increased volume of distribution, increased pre-systemic
clearance, increased metabolism or excretion, decreased
protein binding, or any combination of these factors.
Given the importance of maintaining therapeutic anti-
malarial blood levels, reductions in DHA blood levels
resulting from such pregnancy-induced pharmacokinetic
changes could potentially worsen clinical outcomes.
In this study, pregnant women had significantly lower
plasma concentrations (AUC) of DHA s compared to
non-pregnant controls. The 90% CI for DHA Cmax,
AUCall and AUCfree ratios in pregnancy compared to
three months postpartum fell within the protocol speci-
fied 0.66-1.50 interval for the ratio. However, the med-
ian total and free AUCs for DHA in pregnant women
were only 62% and 79% of the median total and free
AUC for DHA in the non-pregnant controls. This
decreased DHA exposure in pregnant women relative to
non-pregnant controls is consistent with increased CL/F
and possibly increased Vd/F during pregnancy.
There are several possible explanations for the appar-
ent paradox of the similarity between DHA levels in
pregnant women compared to levels in these women at
three months postpartum but reduced levels compared
to non-pregnant women controls. First, there are a vari-
ety of physiological and genetic factors that affect drug
absorption, distribution and metabolism. A comparison
of pharmacokinetic parameters in the same women dur-
ing and after pregnancy mitigates the effect of most
these potential confounders. Second, it is possible that
many of the physiological changes that occur during
pregnancy remain three months postpartum and
continue to differentiate postpartum women from
Table 4 DHA noncompartmental pharmacokinetic data in pregnant, postpartum, and non-pregnant women with
Plasmodium falciparum infection
Antepartum vs. Postpartum* Antepartum vs. Non-pregnant controls† Postpartum vs. Non-pregnant controls†
Parameters Estimate
(90% CI)
P-value Estimate
(90% CI)
P-value Estimate
(90% CI)
P-value
Cmax (ng/mL) 1.06 (0.87, 1.30) 0.62 0.81 (0.63, 1.03) 0.15 0.77 (0.61, 0.98) 0.070
Tmax (h) 0.99 (0.74, 1.33) 0.95 0.90 (0.66, 1.23) 0.58 0.89 (0.67, 1.17) 0.47
AUCall (ng*h/mL) 0.87 (0.77, 0.98) 0.064 0.68 (0.57, 0.81) 0.0004 0.78 (0.66, 0.92) 0.014
AUCfree (ng*h/mL) 0.99 (0.85, 1.15) 0.92 0.78 (0.63, 0.95) 0.039 0.78 (0.65, 0.95) 0.038
CL/F (L/h) 1.21 (1.09, 1.33)‡ 0.0075 1.48 (1.24, 1.76) 0.0004 1.29 (1.09, 1.52) 0.014
CL/F (L/kg/h) 1.16 (1.03, 1.29)‡ 0.040 1.36 (1.18, 1.57) 0.0008 1.24 (1.07, 1.44) 0.016
T½ (h) 0.84 (0.75, 0.96) 0.028 0.86 (0.72, 1.02) 0.15 1.03 (0.86, 1.22) 0.80
Vd/F (L) 0.97 (0.83, 1.14) 0.74 1.26 (1.00, 1.60) 0.097 1.32 (1.04, 1.67) 0.056
Vd/F (L/kg) 0.95 (0.81, 1.12) 0.61 1.18 (0.96, 1.44) 0.19 1.26 (1.02, 1.56) 0.073
FF 1.14 (1.05, 1.24) 0.013 1.15 (1.02, 1.28) 0.051 1.01 (0.89, 1.14) 0.92
Relative estimates (90% CIs) and parametric tests for group comparisons.
* Geometric mean antepartum:postpartum ratio and 90% CI; 1-sample t-test on logged ratios.
† Ratio of geometric means and 90% CI; 2-sample t-test on logged data.
‡ Mean antepartum:postpartum ratio and 90% CI; 1-sample t-test on ratio.
Figure 2 Unbound DHA AUC versus body weight, by subject
group.
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Page 7 of 10non-pregnant women. Only a few of the postpartum
women were parasitaemic at the time of their repeat
evaluation, which may also impact DHA pharmacoki-
netics. Finally, all women were lactating at three months
post-partum; it is possible that lactation effects drug
disposition.
Although the 90% confidence intervals for the DHA
pharmacokinetic parameter ratios for the pregnant and
postpartum subjects were within the 0.66-1.50 equiva-
lence interval, the median values of AUCall and CL/F,
but not Vd/F, in the postpartum subjects were trending
toward those in the non-pregnant parallel-group sub-
jects. Therefore, if the non-pregnant control group phar-
macokinetic parameter estimates are representative of
the pre-pregnant pharmacokinetics of the pregnant/
post-partum group, then the return of pharmacokinetic
parameters to presumed baseline may not have occurred
completely at three months postpartum.
There are few previous pharmacokinetic studies in
which postpartum subjects were compared intrasubject
to the pregnant state. In a study of caffeine during and
after pregnancy, the pharmacokinetics returned to pre-
dicted values in non-pregnant women within 4 days post-
partum [27]. In another study, the estimated mean
midazolam pharmacokinetic parameters, which reflected
significantly decreased AUC and Cmax corresponding
with increased apparent clearance during pregnancy, had
returned to apparent normal in the postpartum period
(weeks 6-10). In the same study, digoxin (p-glycoprotein
substrate) pharmacokinetic parameters had also returned
to normal by the post-partum period [28]. A multi-site,
multi-country study on the pharmacokinetics of sulpha-
doxine and pyrimethamine during pregnancy and the
postpartum period showed variable results by site and an
inconsistency with pharmacokinetic parameters pre-
viously reported in the literature [29]. Lactation state has
also been shown to modify alcohol pharmacokinetics in
women [30]. Based on these examples, the time course to
return to apparent “baseline” may, among other explana-
tions, be chemotype-specific, lactation-state dependent,
or pharmacogenomically-influenced. That there were
inconsistencies reported for sulfadoxine-pyrimethamine
both within- and between studies suggests that caution
should be exercised in making dosing decisions based on
a single study.
The presence of parasitaemia could potentially be con-
tributing to the difference between the postpartum
women and the non-pregnant controls, given that
malaria infection itself may lead to altered pharmacoki-
netics [31]. Although all subjects in the present study,
including postpartum subjects, were PCR-confirmed
parasitaemic at screening prior to treatment with AS,
only two of the postpartum women were parasitaemic
by microscopy of Giemsa-stained blood films at the
time of their pharmacokinetic assessments. Whether dif-
ferences in parasitaemia influenced differences in phar-
macokinetic parameter estimates is unknown. However,
subjects were asymptomatic with low levels of parasites,
which suggests that the influence of parasitaemia on
pharmacokinetic parameter estimates may be minimal.
A prior study conducted by McGready et al in
Thailand suggested that pregnancy was associated with
decreased exposure to DHA, and increased DHA CL/F
and Vd/F, as compared to results obtained in previous
studies with non-pregnant adults [16]. This study evalu-
ated the pharmacokinetics of DHA following AS admin-
istration using samples from the final day of a three day
course of treatment for acute uncomplicated falciparum
malaria in second and third trimester pregnant women.
Their reported median value for DHA CL/F is higher
than the values determined here, as well as higher than
previously reported by Newton et al in non-pregnant
patients with falciparum malaria during the acute or
convalescent phase of infection [32]. The median DHA
Vd/F observed in the McGready study (3.4 L/kg; 90%
range 0.9-60.7) was also somewhat higher than the value
observed in our analysis. This difference could, in part,
be due to the fact that the women in the McGready
s t u d yw e r eg i v e nad i f f e r e n td o s a g eo fa r t e s u n a t e
(4 mg/kg) in conjunction with Malarone
®. However, the
substantially greater degree of variability in DHA CL/F
and Vd/F observed in the McGready study as compared
to our study, as well as a lack of a postpartum or non-
pregnant control group, complicates a direct comparison
of findings.
Both the pregnant women and non-pregnant controls
in our study displayed rapid clearance of parasitaemia
following administration of the 200 mg oral dose of AS.
Differences in parasite clearance were not detected
between the groups, despite the lower DHA AUC of the
pregnant women. However, the possibility that a higher
dose of AS in pregnancy, especially in larger women,
would enhance the parasite clearance cannot be
excluded.
No apparent AS toxicity to either mother or child was
observed in this study. Concerns about the safety of
artemisinin derivatives in pregnancy indicate that toxi-
city may be confined to the first trimester, with studies
in rodents and primates suggesting that the artemisinin
derivatives may be embryotoxic [14]. The positive safety
findings of this study provide additional evidence that
any toxicity risk of first trimester use may not extend
into later periods of gestation.
Conclusions
Oral AS was found to be effective and without adverse
effects in this study of Congolese pregnant women. No
clinically relevant differences were seen in DHA
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Page 8 of 10pharmacokinetics between treated pregnant women and
the same women three months postpartum. In contrast,
the pregnant women had much lower AUCs than non-
pregnant controls. These results suggest that further
studies on the pharmacokinetics of AS in pregnant
women are needed.
Additional material
Additional file 1: Changes in biochemical markers following AS
administration. All biochemical marker values given as mean ± standard
deviation.
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